Trial · NCT05228821
Voxelotor Brain Oxygenation and Neurocognitive Study
NCT05228821, Phase 4, Withdrawn, Pfizer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Voxelotor Brain Oxygenation and Neurocognitive Study. Trials, record NCT05228821. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05228821
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Voxelotor Brain Oxygenation and Neurocognitive Study
- NCT number
- NCT05228821
- Status
- Withdrawn
- Phases
- Phase 4
- Enrollment
- 0 participants, actual
- Lead sponsor
- Pfizer
- Conditions
- Sickle Cell Disease
- Interventions
- Voxelotor Oral Tablet
- First posted
- 2022-02-08
- Last updated
- 2024-08-09
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in CBF | Baseline to Week 24 | Change from Baseline in CBF through Week 24 measured by magnetic resonance imaging (MRI) using pseudo-continuous arterial spin labeling (pCASL). |
| Secondary | Change in executive functioning. | Baseline to Week 24 | Change from Baseline through Week 24 in the executive cognitive abilities composite score (using Dimensional Change Card Sort Test, Flanker Inhibitory Control and Attention Test, and List Sorting Test) as assessed by the National Institutes of Health Toolbox Cognition Module. |
| Secondary | Change in processing speed | Baseline to Week 24 | Change from Baseline through Week 24 in processing speed (using Pattern Comparison Test) as assessed by the NIH Toolbox Cognition Module |
| Secondary | Change in nonexecutive functioning | Baseline to Week 24 | Change from Baseline through Week 24 in nonexecutive cognitive abilities composite score (using Picture Vocabulary Test, Oral Reading Recognition Test, and Picture Sequence Memory Test) as assessed by the NIH Toolbox Cognition Module. |
| Other | Change in Hb and hemolysis over time | Baseline to week 24 | Change and percent change from Baseline through Week 24 in hemolysis measures, including unconjugated bilirubin, absolute reticulocyte, % reticulocytes, and lactate dehydrogenase (LDH). |
| Other | Change in cerebral dynamics | Baseline to week 24 | Change from baseline through Week 24 in cerebral blood flow, oxygen extraction, and oxygen metabolism as measured by diffusion correlation spectroscopy (DCS)/frequency domain near infrared spectroscopy (FDNIRS) (if available) Correlation of cerebral hemodynamics measured by DCS/FDNIRS (if available) and cerebral hemodynamics measured by MRI. |
| Other | Change in global OEF as measured using T2-Relaxation-Under-Spin-Tagging (TRUST) | Baseline to week 24 | Change from Baseline to Week 24 in global OEF as measured using TRUST (if available)). |
| Other | Change in regional CBF within the grey matter | Baseline to Week 24 | Change from Baseline through Week 24 in regional CBF within the grey matter. |
| Other | Change in regional CBF within the white matter | Baseline to Week 24 | Change in HRQOL scores using: Change from Baseline through Week 24 in regional CBF within the white matter |
| Other | Change in regional OEF as measured using ASE (If available) | Baseline to week 24 | Change from Baseline to Week 24 in regional OEF as measured using ASE (if available) |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Dimensional Change Card Sort | Secondary outcome | ConductCognition |
| Pattern and Letter Comparison | Secondary outcome | ConductCognition |
| Picture Order Memory Test | Secondary outcome | ConductCognition |
| Size Order Memory Test | Secondary outcome | ConductCognition |
| Vocabulary Test | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05228821
GET https://conductscience.org/api/trials/v1/NCT05228821/registered